NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
24,019.01 +481.43 (+2.05%)
Biodesix, Inc. (BDSX)
- Business Wire
Biodesix to Present at the H.C. Wainwright Global Investment Conference
BOULDER, Colo., May 17, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
- Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
BOULDER, Colo., May 12, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022, in San Francisco, California.
- Zacks
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
